初治激素受体阳性、HER-2阴性转移性乳腺癌的最佳治疗方案 - Suppr

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

作者信息

Bilgin Burak, Şendur Mehmet An, Hızal Mutlu, Akıncı Muhammed Bülent, Dede Didem Şener, Yalçın Bülent

机构信息

Department of Medical Oncology, Yıldırım Beyazıt University, Ankara, Turkey.

出版信息

Future Oncol. 2019 Jan;15(2):105-107. doi: 10.2217/fon-2018-0086. Epub 2018 Nov 28.

DOI:10.2217/fon-2018-0086

PMID:30484708

Abstract

摘要

相似文献

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

Future Oncol. 2019 Jan;15(2):105-107. doi: 10.2217/fon-2018-0086. Epub 2018 Nov 28.

High-dose chemotherapy for triple negative breast cancer.

Ann Oncol. 2007 Jan;18(1):202-203. doi: 10.1093/annonc/mdl306. Epub 2006 Sep 13.

Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.

J BUON. 2019 Sep-Oct;24(5):2205.

Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Acta Oncol. 2019 Mar;58(3):385-387. doi: 10.1080/0284186X.2019.1566771. Epub 2019 Feb 23.

Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression.

Front Immunol. 2021 Feb 22;12:610149. doi: 10.3389/fimmu.2021.610149. eCollection 2021.

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.

Breast Cancer Res Treat. 2017 Nov;166(1):167-177. doi: 10.1007/s10549-017-4404-4. Epub 2017 Jul 27.

Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.

Tumour Biol. 2018 Nov;40(10):1010428318811025. doi: 10.1177/1010428318811025.

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.

Future Oncol. 2015;11(16):2251-4. doi: 10.2217/fon.15.134.

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.

Clin Breast Cancer. 2016 Dec;16(6):444-455. doi: 10.1016/j.clbc.2016.06.004. Epub 2016 Jun 14.

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).

Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

作者信息

机构信息

出版信息

相似文献